| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A human partial recombinant protein corresponding to amino acids 23-134 was used as the immunogen for the LGALS13 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
LGALS13 Antibody / Galectin 13 is a research-use primary antibody intended for detection of LGALS13 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone PP13/1165, isotype Mouse IgG2b, kappa. Applications listed for this product include ELISA, IHC-P. Reported/annotated localization context: Cytoplasmic, cell surface. Species reactivity (as provided): Human.
Key elements and design rationale
- Target: LGALS13 (Galectin 13) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
- Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
- Antibody identity: Mouse, Monoclonal (mouse origin), clone PP13/1165, isotype Mouse IgG2b, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
- Localization: Cytoplasmic, cell surface — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
- Product notes (from provided description): It recognizes a 32kDa protein, which is identified as homodimer of LGALS13/Galectin 13 (also known as PP13). Galectins are a family of soluble β-galactoside-binding lectins that modulate cell-to-cell adhesion and cell-to-extracellular matrix (ECM) interactions and play a role in tumor progression, pre-mRNA splicing and apoptosis. One such member, LGALS13, is a 139 amino acid protein that contains one galectin domain. Possessing lysophospholipase activity, LGALS13 exists as a disulfide-linked homodimer. LGALS13 is suggested to have a developmental role in the placenta and may display immunobiological activity in feto-maternal blood-spaces. Screening for LGALS13/Galectin 13 in maternal serum during the first trimester of pregnancy may serve as a diagnostic marker to predict preterm pre-eclampsia.
Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.
Biological background
In this catalog, LGALS13 is positioned within Molecular & Cellular Biology, Tumor research contexts. Localization annotations (e.g., Cytoplasmic, cell surface) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.
Research relevance and current trends
- Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
- Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
- Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.
Common research applications
- ELISA: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- Typical workflow themes: IHC on FFPE tissue, ELISA binding assay, Specificity controls.
- Workflow notes: Detect LGALS13 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to LGALS13 peptide/protein by ELISA with dilution series (include blanks), Confirm specificity using KO/KD or pept…
When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.
Notes for experimental interpretation
- Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
- Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
- Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.
Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
